Unveiling Phylos: Revolutionizing Cannabis Genetics with $1.8 Million in Funding

Phylos, a leading innovator in cannabis genetics, has successfully secured $1.8 million in its latest funding round, a significant boost that underscores the growing confidence in the cannabis industry's future. This funding will empower Phylos to enhance its mission of supporting cannabis cultivators of all sizes by further developing its industry-disrupting Production-Ready Seed™. These premium, phenotypically stable, fully-feminized F1 hybrid seeds are designed to produce the highest quality cannabis while optimizing grower profitability. With a commitment to excellence and efficiency, Phylos is already setting a new standard in commercial-scale cultivation, and this new capital will allow the company to accelerate research and development efforts, expand its offerings, and improve its proprietary technologies. In addition to its elite seed products, Phylos is dedicated to providing partners with exceptional THCV genetics and natural ingredient solutions crafted through its expertise in cultivation, extraction, and formulation. As the cannabis market continues to evolve, this funding round positions Phylos as a key player in ensuring that growers can achieve their commercial objectives with cutting-edge solutions. With a clear vision and strategic focus, Phylos is not only paving the way for enhanced crop quality and yield, but it is also actively contributing to the sustainable advancement of the cannabis industry. This significant financial backing marks an exciting chapter in Phylos' journey, reinforcing its role as a catalyst for growth within the sector.